These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10096580)

  • 1. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).
    Gringeri A; Musicco M; Hermans P; Bentwich Z; Cusini M; Bergamasco A; Santagostino E; Burny A; Bizzini B; Zagury D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):358-70. PubMed ID: 10096580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization.
    Gringeri A; Santagostino E; Mannucci PM; Tradati F; Cultraro D; Buzzi A; Criscuolo M; David A; Guillemot L; Barré-Sinoussi F
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):978-88. PubMed ID: 7914235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report.
    Gringeri A; Santagostino E; Cusini M; Muça-Perja M; Marinoni A; Mannucci PM; Burny A; Criscuolo M; Lu W; Andrieru JM; Mbika JP; Lachgar A; Fall LS; Chams V; Feldman M; Hermans P; Zagury JF; Bizzini B; Musicco M; Zagury D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Sep; 13(1):55-67. PubMed ID: 8797687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression.
    Gringeri A; Santagostino E; Mannucci PM; Siracusano L; Marinoni A; Criscuolo M; Carcagno M; Fall LS; M'Bika JP; Bizzini B
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):381-7. PubMed ID: 7580831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy.
    Zagury D; Lecoq H; Gervi I; Le Buanec H; Zagury JF; Bizzini B; Burny A; Hermans P; Perja M; Santagostino E; Gringeri A
    Biomed Pharmacother; 1999 Mar; 53(2):90-2. PubMed ID: 10337463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
    Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial.
    Leal L; Couto E; Sánchez-Palomino S; Climent N; Fernández I; Miralles L; Romero Y; González T; Maleno MJ; Paño B; Pich J; Nicolau C; Gatell JM; Plana M; García F;
    Front Immunol; 2021; 12():767370. PubMed ID: 34858423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial.
    Lane HC; Davey V; Kovacs JA; Feinberg J; Metcalf JA; Herpin B; Walker R; Deyton L; Davey RT; Falloon J
    Ann Intern Med; 1990 Jun; 112(11):805-11. PubMed ID: 1971503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
    Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
    PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
    Reither K; Katsoulis L; Beattie T; Gardiner N; Lenz N; Said K; Mfinanga E; Pohl C; Fielding KL; Jeffery H; Kagina BM; Hughes EJ; Scriba TJ; Hanekom WA; Hoff ST; Bang P; Kromann I; Daubenberger C; Andersen P; Churchyard GJ
    PLoS One; 2014; 9(12):e114602. PubMed ID: 25490675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218).
    Lambert JS; McNamara J; Katz SL; Fenton T; Kang M; VanCott TC; Livingston R; Hawkins E; Moye J; Borkowsky W; Johnson D; Yogev R; Duliege AM; Francis D; Gershon A; Wara D; Martin N; Levin M; McSherry G; Smith G
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):451-61. PubMed ID: 9859958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects.
    Emery S; Workman C; Puls RL; Bloch M; Baker D; Bodsworth N; Anderson J; Crowe SM; French MA; Hoy J; Aichelburg A; Ward LD; Boyle DB; Law MG; Kelleher AD; Cooper DA
    Hum Vaccin; 2005; 1(6):232-8. PubMed ID: 17012863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
    Autran B; Murphy RL; Costagliola D; Tubiana R; Clotet B; Gatell J; Staszewski S; Wincker N; Assoumou L; El-Habib R; Calvez V; Walker B; Katlama C;
    AIDS; 2008 Jul; 22(11):1313-22. PubMed ID: 18580611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
    AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children.
    Palma P; Romiti ML; Li Pira G; Montesano C; Mora N; Aquilani A; Santilli V; Tchidjou HK; Ivaldi F; Giovannelli L; Pontrelli G; Borra G; Blomberg P; Gudmundsdotter L; Bråve A; Montano M; Bernardi S; Manca F; Wahren B; Rossi P
    Vaccine; 2011 Sep; 29(39):6810-6. PubMed ID: 21216310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.
    Vardas E; Kaleebu P; Bekker LG; Hoosen A; Chomba E; Johnson PR; Anklesaria P; Birungi J; Barin B; Boaz M; Cox J; Lehrman J; Stevens G; Gilmour J; Tarragona T; Hayes P; Lowenbein S; Kizito E; Fast P; Heald AE; Schmidt C
    AIDS Res Hum Retroviruses; 2010 Aug; 26(8):933-42. PubMed ID: 20666584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).
    Valentine FT; Kundu S; Haslett PA; Katzenstein D; Beckett L; Spino C; Borucki M; Vasquez M; Smith G; Korvick J; Kagan J; Merigan TC
    J Infect Dis; 1996 Jun; 173(6):1336-46. PubMed ID: 8648205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders.
    Goldwater PN
    Vaccine; 1994 Apr; 12(5):410-4. PubMed ID: 8023548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.